The chronic lymphocytic leukemia (CLL) market has been pegged to grow over the next nine years, with sales of major drugs in the US, Japan and the five major EU markets almost doubling from $3.5bn in 2016 to $6.1bn in 2025, Datamonitor Healthcare reports.
Between 2016 and 2025, the CLL market will see current therapies, such as AbbVie Inc./Johnson & Johnson's Imbruvica...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

